Skip to main content
Erschienen in: Pediatric Nephrology 12/2018

25.07.2018 | Original Article

Does idiopathic hypercalciuria affect bone metabolism during childhood? A prospective case-control study

verfasst von: Maria Pavlou, Vasileios Giapros, Anna Challa, Nikolaos Chaliasos, Ekaterini Siomou

Erschienen in: Pediatric Nephrology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

A limited number of studies have evaluated biochemical bone metabolism markers in children with idiopathic hypercalciuria, which in adults has been linked with osteopenia. Our aim was to investigate in children with idiopathic hypercalciuria biochemical markers of bone formation and resorption and the osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kB ligand (sRANKL) system which is involved in the osteoclastogenesis process.

Methods

A prospective study was conducted on 50 children with idiopathic hypercalciuria and 50 healthy age-, sex-, and Tanner stage-matched control subjects. Following the diagnosis, patients were requested to follow a 3-month dietary recommendation for idiopathic hypercalciuria. In patients, at diagnosis and at 3 months of follow-up, and in controls, bone-related hormones and serum/urine biochemical parameters were studied. The bone formation markers (total ALP and osteocalcin) and the bone resorption markers (β-Crosslaps) and the OPG and sRANKL levels were determined.

Results

No differences were found in the bone formation markers or OPG and sRANKL between the children with idiopathic hypercalciuria and controls. The β-Crosslaps and the β-Crosslaps/osteocalcin ratio were higher in the patients at diagnosis than in controls (p = 0.019 and p = 0.029, respectively), with a trend to decrease after the 3-month dietary intervention. The initially increased 24-h urinary Ca in the patients decreased after the 3-month dietary intervention (p = 0.002).

Conclusions

Children with idiopathic hypercalciuria had biochemical markers compatible with normal bone formation but increased bone resorption. After a 3-month dietary intervention, the trend observed towards decrease in the serum β-Crosslaps may reflect a beneficial response.
Literatur
1.
Zurück zum Zitat Schwaderer AL, Cronin R, Mahan JD, Bates CM (2008) Low bone density in children with hypercalciuria and/or nephrolithiasis. Pediatr Nephrol 23:2209–2214CrossRefPubMed Schwaderer AL, Cronin R, Mahan JD, Bates CM (2008) Low bone density in children with hypercalciuria and/or nephrolithiasis. Pediatr Nephrol 23:2209–2214CrossRefPubMed
2.
3.
Zurück zum Zitat Escribano J, Rubio-Torrents C, Ferre N, Luque V, Grote V, Zaragoza-Jordana M, Gispert-Llaurado M, Closa-Monasterolo R, European Childhood Obesity Project Group (2014) Reduced bone mass in 7-year-old children with asymptomatic idiopathic hypercalciuria. Ann Nutr Metab 64:304–313CrossRefPubMed Escribano J, Rubio-Torrents C, Ferre N, Luque V, Grote V, Zaragoza-Jordana M, Gispert-Llaurado M, Closa-Monasterolo R, European Childhood Obesity Project Group (2014) Reduced bone mass in 7-year-old children with asymptomatic idiopathic hypercalciuria. Ann Nutr Metab 64:304–313CrossRefPubMed
4.
Zurück zum Zitat Yousefichaijan P, Rafiei M, Aziminejad A, Pakniyat A (2015) The prevalence of hypercalciuria in girl kids with over active bladder. J Renal Inj Prev 4:117–119PubMedCentralPubMed Yousefichaijan P, Rafiei M, Aziminejad A, Pakniyat A (2015) The prevalence of hypercalciuria in girl kids with over active bladder. J Renal Inj Prev 4:117–119PubMedCentralPubMed
5.
Zurück zum Zitat Srivastava T, Schwaderer A (2009) Diagnosis and management of hypercalciuria in children. Curr Opin Pediatr 21:214–219CrossRefPubMed Srivastava T, Schwaderer A (2009) Diagnosis and management of hypercalciuria in children. Curr Opin Pediatr 21:214–219CrossRefPubMed
6.
Zurück zum Zitat Polito C, La Manna A, Cioce F, Villani J, Nappi B, Di Toro R (2000) Clinical presentation and natural course of idiopathic hypercalciuria in children. Pediatr Nephrol 15:211–214CrossRefPubMed Polito C, La Manna A, Cioce F, Villani J, Nappi B, Di Toro R (2000) Clinical presentation and natural course of idiopathic hypercalciuria in children. Pediatr Nephrol 15:211–214CrossRefPubMed
7.
Zurück zum Zitat Penido MG, Lima EM, Marino VS, Tupinamba AL, Franca A, Souto MF (2003) Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis. Pediatr Nephrol 18:133–139PubMed Penido MG, Lima EM, Marino VS, Tupinamba AL, Franca A, Souto MF (2003) Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis. Pediatr Nephrol 18:133–139PubMed
8.
Zurück zum Zitat Garcia-Nieto V, Ferrandez C, Monge M, de Sequera M, Rodrigo MD (1997) Bone mineral density in pediatric patients with idiopathic hypercalciuria. Pediatr Nephrol 11:578–583CrossRefPubMed Garcia-Nieto V, Ferrandez C, Monge M, de Sequera M, Rodrigo MD (1997) Bone mineral density in pediatric patients with idiopathic hypercalciuria. Pediatr Nephrol 11:578–583CrossRefPubMed
9.
Zurück zum Zitat Artemiuk I, Panczyk-Tomaszewska M, Adamczuk D, Przedlacki J, Roszkowska-Blaim M (2015) Bone mineral density in children with idiopathic Hypercalciuria. Dev Period Med 19:356–361PubMed Artemiuk I, Panczyk-Tomaszewska M, Adamczuk D, Przedlacki J, Roszkowska-Blaim M (2015) Bone mineral density in children with idiopathic Hypercalciuria. Dev Period Med 19:356–361PubMed
10.
11.
Zurück zum Zitat Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR (2002) Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant 17:1396–1401CrossRefPubMed Freundlich M, Alonzo E, Bellorin-Font E, Weisinger JR (2002) Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers. Nephrol Dial Transplant 17:1396–1401CrossRefPubMed
12.
Zurück zum Zitat Polito C, Iolascon G, Nappi B, Andreoli S, La Manna A (2003) Growth and bone mineral density in long-lasting idiopathic hypercalciuria. Pediatr Nephrol 18:545–547PubMed Polito C, Iolascon G, Nappi B, Andreoli S, La Manna A (2003) Growth and bone mineral density in long-lasting idiopathic hypercalciuria. Pediatr Nephrol 18:545–547PubMed
13.
Zurück zum Zitat Horowitz MC, Xi Y, Wilson K, Kacena MA (2001) Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12:9–18CrossRefPubMed Horowitz MC, Xi Y, Wilson K, Kacena MA (2001) Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12:9–18CrossRefPubMed
14.
Zurück zum Zitat Stapleton FB (1994) Hematuria associated with hypercalciuria and hyperuricosuria: a practical approach. Pediatr Nephrol 8:756–761CrossRefPubMed Stapleton FB (1994) Hematuria associated with hypercalciuria and hyperuricosuria: a practical approach. Pediatr Nephrol 8:756–761CrossRefPubMed
15.
Zurück zum Zitat Siener R, Hesse A (2003) Fluid intake and epidemiology of urolithiasis. Eur J Clin Nutr 57(Suppl 2):S47–S51CrossRefPubMed Siener R, Hesse A (2003) Fluid intake and epidemiology of urolithiasis. Eur J Clin Nutr 57(Suppl 2):S47–S51CrossRefPubMed
16.
Zurück zum Zitat Pencharz PB, Elango R, Wolfe RR (2016) Recent developments in understanding protein needs - how much and what kind should we eat? Appl Physiol Nutr Metab 41:577–580CrossRefPubMed Pencharz PB, Elango R, Wolfe RR (2016) Recent developments in understanding protein needs - how much and what kind should we eat? Appl Physiol Nutr Metab 41:577–580CrossRefPubMed
17.
Zurück zum Zitat Alon US, Zimmerman H, Alon M (2004) Evaluation and treatment of pediatric idiopathic urolithiasis-revisited. Pediatr Nephrol 19:516–520CrossRefPubMed Alon US, Zimmerman H, Alon M (2004) Evaluation and treatment of pediatric idiopathic urolithiasis-revisited. Pediatr Nephrol 19:516–520CrossRefPubMed
18.
Zurück zum Zitat Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Gelosa M, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F (2015) Dietary treatment of urinary risk factors for renal stone formation. A review of CLU working group. Arch Ital Urol Androl 87:105–120CrossRefPubMed Prezioso D, Strazzullo P, Lotti T, Bianchi G, Borghi L, Caione P, Carini M, Caudarella R, Ferraro M, Gambaro G, Gelosa M, Guttilla A, Illiano E, Martino M, Meschi T, Messa P, Miano R, Napodano G, Nouvenne A, Rendina D, Rocco F, Rosa M, Sanseverino R, Salerno A, Spatafora S, Tasca A, Ticinesi A, Travaglini F, Trinchieri A, Vespasiani G, Zattoni F (2015) Dietary treatment of urinary risk factors for renal stone formation. A review of CLU working group. Arch Ital Urol Androl 87:105–120CrossRefPubMed
19.
Zurück zum Zitat Meacham S, Grayscott D, Chen JJ, Bergman C (2008) Review of the dietary reference intake for calcium: where do we go from here? Crit Rev Food Sci Nutr 48:378–384CrossRefPubMed Meacham S, Grayscott D, Chen JJ, Bergman C (2008) Review of the dietary reference intake for calcium: where do we go from here? Crit Rev Food Sci Nutr 48:378–384CrossRefPubMed
21.
Zurück zum Zitat Hess B, Jaeger P (1993) The tale of parathyroid function in idiopathic hypercalciuria. Scanning Microsc 7:403–408PubMed Hess B, Jaeger P (1993) The tale of parathyroid function in idiopathic hypercalciuria. Scanning Microsc 7:403–408PubMed
22.
Zurück zum Zitat Rauch F, Middelmann B, Cagnoli M, Keller KM, Schonau E (1997) Comparison of total alkaline phosphatase and three assays for bone-specific alkaline phosphatase in childhood and adolescence. Acta Paediatr 86:583–587CrossRefPubMed Rauch F, Middelmann B, Cagnoli M, Keller KM, Schonau E (1997) Comparison of total alkaline phosphatase and three assays for bone-specific alkaline phosphatase in childhood and adolescence. Acta Paediatr 86:583–587CrossRefPubMed
23.
Zurück zum Zitat Ticinesi A, Nouvenne A, Maalouf NM, Borghi L, Meschi T (2016) Salt and nephrolithiasis. Nephrol Dial Transplant 31:39–45CrossRefPubMed Ticinesi A, Nouvenne A, Maalouf NM, Borghi L, Meschi T (2016) Salt and nephrolithiasis. Nephrol Dial Transplant 31:39–45CrossRefPubMed
24.
Zurück zum Zitat Arrabal-Polo MA, Sierra Giron-Prieto M, Orgaz-Molina J, Zuluaga-Gomez A, Arias-Santiago S, Arrabal-Martin M (2013) Calcium renal lithiasis and bone mineral density. Importance of bone metabolism in urinary lithiasis. Actas Urol Esp 37:362–367CrossRefPubMed Arrabal-Polo MA, Sierra Giron-Prieto M, Orgaz-Molina J, Zuluaga-Gomez A, Arias-Santiago S, Arrabal-Martin M (2013) Calcium renal lithiasis and bone mineral density. Importance of bone metabolism in urinary lithiasis. Actas Urol Esp 37:362–367CrossRefPubMed
25.
Zurück zum Zitat Arrabal-Polo MA, Arrabal-Martin M, Giron-Prieto MS, Orgaz-Molina J, Quesada-Charneco M, Lopez-Ruiz A, Poyatos-Andujar A, Zuluaga-Gomez A, Arias-Santiago S (2013) Association of severe calcium lithogenic activity and bone remodeling markers. Urology 82:16–21CrossRefPubMed Arrabal-Polo MA, Arrabal-Martin M, Giron-Prieto MS, Orgaz-Molina J, Quesada-Charneco M, Lopez-Ruiz A, Poyatos-Andujar A, Zuluaga-Gomez A, Arias-Santiago S (2013) Association of severe calcium lithogenic activity and bone remodeling markers. Urology 82:16–21CrossRefPubMed
26.
Zurück zum Zitat Arrabal-Polo MA, Arrabal-Martin M, de Haro-Munoz T, Poyatos-Andujar A, Palaeo-Yago F, Zuluaga-Gomez A (2012) Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis. Urology 79:48–54CrossRefPubMed Arrabal-Polo MA, Arrabal-Martin M, de Haro-Munoz T, Poyatos-Andujar A, Palaeo-Yago F, Zuluaga-Gomez A (2012) Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis. Urology 79:48–54CrossRefPubMed
27.
Zurück zum Zitat Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319CrossRefPubMed
28.
Zurück zum Zitat Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463–474CrossRefPubMedPubMedCentral Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463–474CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602CrossRefPubMedPubMedCentral Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95:3597–3602CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ (2009) Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45:669–676CrossRefPubMed Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ (2009) Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45:669–676CrossRefPubMed
31.
Zurück zum Zitat Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235–244CrossRefPubMed Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235–244CrossRefPubMed
32.
Zurück zum Zitat Gomes SA, dos Reis LM, Noronha IL, Jorgetti V, Heilberg IP (2008) RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol 3:1446–1452CrossRefPubMedPubMedCentral Gomes SA, dos Reis LM, Noronha IL, Jorgetti V, Heilberg IP (2008) RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol 3:1446–1452CrossRefPubMedPubMedCentral
Metadaten
Titel
Does idiopathic hypercalciuria affect bone metabolism during childhood? A prospective case-control study
verfasst von
Maria Pavlou
Vasileios Giapros
Anna Challa
Nikolaos Chaliasos
Ekaterini Siomou
Publikationsdatum
25.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 12/2018
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-018-4027-y

Weitere Artikel der Ausgabe 12/2018

Pediatric Nephrology 12/2018 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.